Toxicities, such as atrial fibrillation, bleeding, or arterial hypertension, albeit limited, caused by inhibition of other non-BTK targets, such as ITK and EGFR underscores the need for more selective BTK inhibitors with fewer off-target effects [6, 11]. The gene discussed is BTK; the disease is atrial fibrillation.